HER2Sense 645 Fluorescent Imaging Agent by Revvity

Revvity's development of HER2Sense™ targeted fluorescent imaging agent offers a highly therapeutically relevant optical probe for breast cancer research.

Novel approaches in therapeutically active optical probes have enabled researchers to follow longitudinal therapeutic response to compounds. Revvity’s development of HER2Sense™ offers a highly therapeutically relevant optical probe for breast cancer research.

HER2Sense is based on the therapeutic antibody, Trastuzumab and Revvity’s proprietary VivoTag® fluorescent dye, optimized for use in living systems. Trastuzumab is a commercialized bio-therapeutic drug from Roche.

The ability to image HER2 can provide an important tool for cancer detection and quantification as well as for the assessment of target coverage for HER2-specific therapies. The pairing of HER2Sense with Revvity imaging systems, and other novel red and near infrared (NIR) imaging agents, allows the detection and quantification of multiple important biological processes in the context of tumor HER2 expression.


HER2Sense 645 Fluorescent Imaging Agent Features & Benefits:

• The first pre-clinical imaging agent to be based on a commercialized therapeutic antibody.
• Because Trastuzumab is well-characterized and validated, HER2Sense enables strong correlation between pre-clinical and clinical research.
• Highly specific for the HER2/neu receptor and avoids systemic immune responses found in other antibodybased imaging agents.
• HER2Sense also enables the interrogation of HER2/neu receptor-expressing non-breast cancer models, such as ovarian cancer, in living animals.